© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
May 6th 2021, 9:00pm
By Colleen Moretti
Compared to a hypomethylating agent alone, combining the agent with Venclexta improved complete remission rates in patients with blast-phase myeloproliferative neoplasm.
May 6th 2021, 6:00pm
By Ryan McDonald
Members of an FDA committee voted in favor of Tecentriq plus Abraxane keeping its accelerated approval for the treatment of adults with unresectable, locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1.
May 6th 2021, 4:00pm
By Kelly Irvin
“We’re all blessed that there are so many dedicated, caring health care professionals willing to step in and fill the void when members of the team move or retire,” writes a patient with cancer. “We can never forget how tough a gig it is or say thank you enough.”
May 6th 2021, 3:00pm
By Jamie Cesanek
In this episode of the “CURE® Talks Cancer” podcast, Leanne Burnham, Ph.D., discusses the research she’s working on to address health disparities in Black men with prostate cancer after being inspired by her father’s diagnosis, and shares her own cancer survival story.
May 6th 2021, 1:52pm
The priority review will focus on the combination of Keytruda and Lenvima for the first-line treatment of advanced renal cell carcinoma, as well as the treatment of certain patients with endometrial carcinoma.
May 6th 2021, 1:00pm
Virtual visits during the COVID-19 pandemic improved satisfaction and convenience, as well as reduced stress and anxiety in veterans who have survived cancer.
May 5th 2021, 9:00pm
FDA committee members recently voted in favor of upholding Tecentriq’s accelerated approval indication for the first-line treatment of certain adults with locally advanced or metastatic urothelial carcinoma who are ineligible for standard chemotherapy.
May 5th 2021, 6:58pm
By Darlene Dobkowski, MA
Based on findings from the KEYNOTE-811 trial, the FDA approved Keytruda for the treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in combination with trastuzumab and chemotherapy.
May 5th 2021, 6:00pm
Women who receive a breast cancer diagnosis were more likely to develop unhealthy behaviors one and two years after diagnosis, even if they were considered healthy at time of diagnosis.
May 5th 2021, 4:00pm
By Jane Biehl Ph.D.
A cancer survivor recalls how a book quote about a blizzard became a metaphor for her own experiences with cancer.
May 5th 2021, 3:00pm
Patients with cancer should receive whichever COVID-19 vaccine is made available to them as the benefits far outweigh the risks, according to an expert from Memorial Sloan Kettering Cancer Center.
May 5th 2021, 1:00pm
Factors including progression-free survival, duration of response and overall survival were promising at 15 months in patients with relapsed/refractory mantle cell lymphoma.
May 4th 2021, 9:00pm
A significant number of patient records in large cancer registries are missing data, which can have an impact on real-world data studies.
May 4th 2021, 6:00pm
There is some low-level evidence that suggests medical marijuana or cannabinoids may reduce chemotherapy-related side effects in patients with cancer, according to data presented at a recent medical conference. However, experts note more research is needed to build on those findings.
May 4th 2021, 4:00pm
By Ron Cooper
A cancer survivor recalls how he never considered a bucket list until his diagnosis in 2014. And although he knows he can’t afford to buy a Ferrari and cruise through the Alps, he’s OK with changing course and going with something much smaller.
This Month in Kidney Cancer Research from the KCA
Meet Maia and Manju, Clinical Trial Champions
Here Today Because of a Whipple Procedure
Got a Bladder Cancer Question? Ask the Experts